Drug intelligence / Profile preview

DPG-001

Development stage: Preclinical
Lead developer: Cellontech
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Injection

Overview

DPG-001 is a preclinical-stage drug delivery material developed by Cellontech, a biotechnology company specializing in regenerative medicine and collagen-based technologies. It is designed as a biocompatible carrier system to facilitate the controlled and sustained release of therapeutic agents. As part of Cellontech's Drug Delivery System (DDS) pipeline, DPG-001 is intended to improve the pharmacokinetic profiles of various drugs by providing a stable matrix for localized or systemic delivery. The material aims to protect active pharmaceutical ingredients from premature degradation and optimize their therapeutic window by regulating release kinetics through diffusion or matrix degradation.

Beyond the preview

Go deeper on DPG-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPG-001.

Explore the full profile